FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200480936> ?p ?o ?g. }

• W4200480936 abstract "Introduction: Approximately 10-20% of patients WITH myasthenia gravis (MG) are refractory to conventional immunotherapies. The purpose of this study was to conduct a systematic review and meta-analysis to explore the optimal therapies for refractory MG. Method: Correlative studies were performed through a search in PubMed, Cochrane Library, and Embase databases. The primary outcome was defined by changes in the quantitative myasthenia gravis score (QMG). Secondary outcomes were defined by the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL), Myasthenia Gravis Foundation of America (MGFA) post intervention status, adverse events, and disease exacerbation after treatment. Result: A total of 16 studies were included with 403 patients with refractory MG on therapies with rituximab, eculizumab, tacrolimus, and cladribine. Therapeutic efficacy of rituximab and eculizumab was identified with an estimated reduction in QMG score (4.158 vs. 6.928) and MG-ADL (4.400 vs. 4.344), respectively. No significant changes were revealed in efficacy or exacerbation density between the two independent therapeutic cohorts. The estimated adverse event density of eculizumab was more significant than that in the rituximab group (1.195 vs. 0.134 per patient-year), while the estimated serious event density was similar. Conclusion: The efficacy and safety of rituximab and eculizumab have been approved in patients with refractory MG. Rituximab had a superior safety profile than eculizumab with a lower incidence of adverse events. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236818, identifier CRD42021236818." @default.
• W4200480936 created "2021-12-31" @default.
• W4200480936 creator A5045268007 @default.
• W4200480936 creator A5063900372 @default.
• W4200480936 creator A5075531567 @default.
• W4200480936 creator A5075936339 @default.
• W4200480936 creator A5078662156 @default.
• W4200480936 creator A5088815874 @default.
• W4200480936 date "2021-12-01" @default.
• W4200480936 modified "2023-10-13" @default.
• W4200480936 title "Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis" @default.
• W4200480936 cites W1946521533 @default.
• W4200480936 cites W1951143273 @default.
• W4200480936 cites W2004265876 @default.
• W4200480936 cites W2034919646 @default.
• W4200480936 cites W2051200447 @default.
• W4200480936 cites W2066571580 @default.
• W4200480936 cites W2069973239 @default.
• W4200480936 cites W2109351747 @default.
• W4200480936 cites W2111680674 @default.
• W4200480936 cites W2118285512 @default.
• W4200480936 cites W2129124562 @default.
• W4200480936 cites W2137544340 @default.
• W4200480936 cites W2156039834 @default.
• W4200480936 cites W2164819810 @default.
• W4200480936 cites W2406546229 @default.
• W4200480936 cites W2555422834 @default.
• W4200480936 cites W2595610815 @default.
• W4200480936 cites W2766784006 @default.
• W4200480936 cites W2789644345 @default.
• W4200480936 cites W2805892265 @default.
• W4200480936 cites W2909823939 @default.
• W4200480936 cites W2912901461 @default.
• W4200480936 cites W2918024729 @default.
• W4200480936 cites W2919659424 @default.
• W4200480936 cites W2944474952 @default.
• W4200480936 cites W2955135410 @default.
• W4200480936 cites W2974168831 @default.
• W4200480936 cites W2983574106 @default.
• W4200480936 cites W3000276814 @default.
• W4200480936 cites W3011996040 @default.
• W4200480936 cites W3023124841 @default.
• W4200480936 cites W3087185069 @default.
• W4200480936 cites W3106936335 @default.
• W4200480936 cites W3110802263 @default.
• W4200480936 cites W3195988597 @default.
• W4200480936 cites W3200795627 @default.
• W4200480936 doi "https://doi.org/10.3389/fneur.2021.725700" @default.
• W4200480936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34925206" @default.
• W4200480936 hasPublicationYear "2021" @default.
• W4200480936 type Work @default.
• W4200480936 citedByCount "7" @default.
• W4200480936 countsByYear W42004809362022 @default.
• W4200480936 countsByYear W42004809362023 @default.
• W4200480936 crossrefType "journal-article" @default.
• W4200480936 hasAuthorship W4200480936A5045268007 @default.
• W4200480936 hasAuthorship W4200480936A5063900372 @default.
• W4200480936 hasAuthorship W4200480936A5075531567 @default.
• W4200480936 hasAuthorship W4200480936A5075936339 @default.
• W4200480936 hasAuthorship W4200480936A5078662156 @default.
• W4200480936 hasAuthorship W4200480936A5088815874 @default.
• W4200480936 hasBestOaLocation W42004809361 @default.
• W4200480936 hasConcept C111684460 @default.
• W4200480936 hasConcept C121332964 @default.
• W4200480936 hasConcept C126322002 @default.
• W4200480936 hasConcept C142424586 @default.
• W4200480936 hasConcept C159654299 @default.
• W4200480936 hasConcept C197934379 @default.
• W4200480936 hasConcept C203014093 @default.
• W4200480936 hasConcept C2776478404 @default.
• W4200480936 hasConcept C2777014857 @default.
• W4200480936 hasConcept C2777991916 @default.
• W4200480936 hasConcept C2778105408 @default.
• W4200480936 hasConcept C2779338263 @default.
• W4200480936 hasConcept C2780653079 @default.
• W4200480936 hasConcept C71924100 @default.
• W4200480936 hasConcept C87355193 @default.
• W4200480936 hasConcept C95190672 @default.
• W4200480936 hasConceptScore W4200480936C111684460 @default.
• W4200480936 hasConceptScore W4200480936C121332964 @default.
• W4200480936 hasConceptScore W4200480936C126322002 @default.
• W4200480936 hasConceptScore W4200480936C142424586 @default.
• W4200480936 hasConceptScore W4200480936C159654299 @default.
• W4200480936 hasConceptScore W4200480936C197934379 @default.
• W4200480936 hasConceptScore W4200480936C203014093 @default.
• W4200480936 hasConceptScore W4200480936C2776478404 @default.
• W4200480936 hasConceptScore W4200480936C2777014857 @default.
• W4200480936 hasConceptScore W4200480936C2777991916 @default.
• W4200480936 hasConceptScore W4200480936C2778105408 @default.
• W4200480936 hasConceptScore W4200480936C2779338263 @default.
• W4200480936 hasConceptScore W4200480936C2780653079 @default.
• W4200480936 hasConceptScore W4200480936C71924100 @default.
• W4200480936 hasConceptScore W4200480936C87355193 @default.
• W4200480936 hasConceptScore W4200480936C95190672 @default.
• W4200480936 hasFunder F4320335777 @default.
• W4200480936 hasLocation W42004809361 @default.
• W4200480936 hasLocation W42004809362 @default.
• W4200480936 hasLocation W42004809363 @default.
• W4200480936 hasLocation W42004809364 @default.
• W4200480936 hasOpenAccess W4200480936 @default.

• next